ⓘ Fasinumab

                                     

ⓘ Fasinumab

Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.

This drug was developed in partnership Teva pharmaceutical industries and Regeneron pharmaceuticals.

She currently is in phase III clinical trials.

                                     
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against
  • SAR - 127963 Testosterone Antibodies: Against NGF: ABT - 110 PG110 ASP - 6294 Fasinumab Frunevetmab Fulranumab MEDI - 578 Ranevetmab Tanezumab Aptamers: Against